Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|
| Dir | Wang Xiaodong | 4.58M | $1.56B | - |
| Pres | Wang Lai | 1.45M | $494.04M | - |
| Dir | BAKER BROS. ADVISORS LP | 148.1K | $50.40M | - |
| Dir | HOOPER ANTHONY C | 64.7K | $22.04M | - |
| Dir | Riva Alessandro | 56.9K | $19.38M | - |
Transactions
14 filings · page 17
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|
| 2021-06-07 | Wu Xiaobin | President, COO & GM China | Sell | 573 | $353.56 | $202,591.18 | -99.7% | → |
| 2021-06-07 | Liang Howard | CFO & Chief Strategy Officer | Sell | 650 | $354.16 | $230,202.50 | -100% | → |
| 2021-06-07 | Wang Lai | Global Head of R&D | Sell | 656 | $354.26 | $232,392.33 | -100% | → |
| 2021-06-07 | Huang Jane | CMO, Hematology | Sell | 603 | $351.55 | $211,985.55 | -100% | → |
| 2021-06-01 | Huang Jane | CMO, Hematology | Sale+OE | 2,040 | $357.98 | $730,280.79 | -38.6% | → |
| 2021-05-10 | Wang Xiaodong | - | Sale+OE | 3,394 | $300.46 | $1,019,751.84 | -50.1% | → |
| 2021-05-03 | Wu Xiaobin | President, COO & GM China | Sell | 6,715 | $343.00 | $2,303,245.00 | -100% | → |
| 2021-04-29 | Huang Jane | CMO, Hematology | Sale+OE | 1,500 | $354.92 | $532,386.99 | -26.3% | → |
| 2021-03-29 | Huang Jane | CMO, Hematology | Sale+OE | 1,500 | $324.00 | $485,992.55 | -36.1% | → |
| 2021-02-26 | Huang Jane | CMO, Hematology | Sale+OE | 1,500 | $320.73 | $481,098.99 | -25.9% | → |
| 2021-01-29 | Huang Jane | CMO, Hematology | Sale+OE | 1,500 | $322.99 | $484,492.15 | -26.3% | → |
| 2021-01-15 | Liang Howard | CFO & Chief Strategy Officer | Sale+OE | 14,000 | $344.85 | $4,827,945.23 | -70.3% | → |
| 2021-01-04 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Sell | 121,154 | $220.50 | $26,714,457.00 | -1.0% | → |
| 2020-12-29 | Huang Jane | CMO, Hematology | Sale+OE | 700 | $246.26 | $172,381.03 | -18.4% | → |